RCAP
SPRB

Resolute Capital Asset Partners’s Spruce Biosciences SPRB Stock Holding History

Resolute Capital Asset Partners’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$261K Hold
4,000
– – 0.14% 41
2025
Q4 		$348K Buy
+4,000
New +$429K 0.17% 47

Other funds holding SPRB

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return

Resolute Capital Asset Partners's SPRB Position: Q1 2026 in Review

Resolute Capital Asset Partners held its Spruce Biosciences (SPRB) position steady in Q1 2026 at 4,000 shares worth $261K. The position accounts for 0.14% of the portfolio, ranked #41.

Resolute Capital Asset Partners first reported a position in SPRB in Q4 2025 and has held it in 2 quarters since. The position peaked at $348K in Q4 2025. 32 funds tracked by Wall St. Rank hold SPRB as of Q1 2026.

  • Resolute Capital Asset Partners held 4,000 shares of Spruce Biosciences worth $261K as of Q1 2026.
  • Resolute Capital Asset Partners left its Spruce Biosciences share count unchanged in Q1 2026.
  • Spruce Biosciences made up 0.14% of Resolute Capital Asset Partners's portfolio in Q1 2026, its #41 holding.
  • Resolute Capital Asset Partners first reported a position in Spruce Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Resolute Capital Asset Partners's Spruce Biosciences position peaked at $348K in Q4 2025.
  • 32 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2026.

Based on Resolute Capital Asset Partners's 13F filing for Q1 2026, filed 15 May 2026.